VIRAMUNE should be initiated according to the CD4+ cell count criteria (VIRAMUNE PI)
Life-threatening and fatal hepatotoxicity has occurred in patients receiving VIRAMUNE. Any patient can experience hepatic events; however, female gender and higher CD4+ cell counts at initiation of therapy place patients at greatest risk. (VIRAMUNE PI)
CD4+ cell counts in treatment-naive patients at the initiation of any ARV
therapy in men and women (Data on file. Boehringer Ingelheim Pharmaceuticals,
Inc.)
Please consult Full Prescribing Information, including boxed WARNING, Medication Guide, and Important Safety Information for VIRAMUNE.
